Agios Pharmaceuticals, Inc. (AGIO)

24.22 -0.53 (-2.14%) At close: 04:00PM EDT

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 389

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brian M. Goff M.B.A.	CEO & Director	1.23M	N/A	1969
Ms. Cecilia Jones	Chief Financial Officer	403.36k	N/A	1975
Mr. James William Burns	Corp. Sec. & Chief Legal Officer	660.33k	N/A	1978
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of R&D	769.2k	N/A	1980
Dr. Lewis Clayton Cantley Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Craig B. Thompson M.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1953
Dr. Shin-San Su Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1956
Mr. T. J. Washburn Jr.	Principal Accounting Officer	N/A	N/A	1981
Dr. Clive Patience Ph.D.	Chief Technical Operations Officer	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.